Dose-related antibody responses to purified Vero cell rabies vaccine in healthy Thai children

被引:0
|
作者
Chanthavanich, P [1 ]
Sabchareon, A [1 ]
Singhasivanon, V [1 ]
Pojjaroen-Anant, C [1 ]
Chongsuphajaisiddhi, T [1 ]
Kittikoon, P [1 ]
机构
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, Bangkok 10400, Thailand
来源
关键词
PVRV; dose-related; children;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To study whether the response to tissue culture rabies vaccine in children is dose related, 82 children aged 7-13 years (mean: 9.5 years), weighing 17-40 kg (mean: 25 kg), were divided randomly into three groups. All of the children received purified Vero cell rabies vaccine 2-1-1 intramuscular regimen (two sites on day 0, one site each on days 7 and 21). Group I (n = 29) received a full dose of 0.5 mt (antigenic value: 7.1 international units [IU]/dose), group II (n = 26) received a half dose of 0.25 mL (antigenic value: 3.55 IU/dose), and group III (n = 27) received a one-third dose of 0.15 mL (antigenic value: 2.13 IU/dose). The rapid fluorescent focus inhibition test (RFFIT) was used to measure the neutralizing antibody (Nab). The results showed that all of the children seroconverted (> 0.5 IU/mL) on day 14. The Nab responses were dose related. The geometric mean titers (GMT) on days 14, 28, 91, and 182 of group I were 23 (range: 4-134), 18 (range: 3-86), 3 (range: 1-25), and 1 (range. < 0.5-18) IU/mL, respectively. The GMT values of group II on the corresponding days were 20 (range: 5-186), 11 (range: 3-159), 1 (range: 0.5-14), and 1 (range: < 0.5-9) IU/mL. Although the Nab levels in group II were lower than those in group I, the differences were not statistically significant. The GMT of group III on days 14 and 28, which were 6 (range: 0.5-29) and 7 (range: 1-29) IU/mL, were significantly lower than those of groups I and II (P < 0.05). However, the GMT on days 91 and 182 of group III, 1 (range: < 0.5-10) and 0.5 (range: < 0.5-7) IU/mL, were not significantly different from those of groups I and II. In conclusion, when antigenic value of rabies vaccine is less than 2.5 IU/dose (group III), the immune response is relatively poor. The doses of rabies post-exposure vaccination in children should not be reduced.
引用
收藏
页码:97 / 100
页数:4
相关论文
共 50 条
  • [31] Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine
    Jones, RL
    Froeschle, JE
    Atmar, RL
    Matthews, JS
    Sanders, R
    Pardalos, J
    Moeller, L
    Chin, JE
    Famula, M
    Briggs, DJ
    VACCINE, 2001, 19 (32) : 4635 - 4643
  • [32] COMPARISON OF HUMAN IMMUNE-RESPONSES TO PURIFIED VERO CELL AND HUMAN-DIPLOID CELL RABIES VACCINES BY USING 2 DIFFERENT ANTIBODY TITRATION METHODS
    KITALA, PM
    LINDQVIST, KJ
    KOIMETT, E
    JOHNSON, BK
    CHUNGE, CN
    PERRIN, P
    OLSVIK, O
    JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (08) : 1847 - 1850
  • [33] Noninferiority Study of Purified Vero Rabies Vaccine-Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines
    Chokephaibulkit, Kulkanya
    Huoi, Catherine
    Tantawichien, Terapong
    Mootsikapun, Piroon
    Kosalaraksa, Pope
    Kiertiburanakul, Sasisopin
    Ratanasuwan, Winai
    Vangelisti, Manuel
    Laot, Thelma
    Huang, Youjun
    Petit, Celine
    Pineda-Pena, Andrea-Clemencia
    Frago, Carina
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [34] Safety and immunogenicity of new chromatographically purified Vero cell rabies vaccine (CPRV) for human use in pre- and post-exposure rabies
    Tantawichien, T.
    Sibunruang, S.
    Angsanakul, J.
    Tantawichien, T.
    Limsuwan, K.
    Khumvilai, S.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S158 - S158
  • [35] Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects
    Shi, Nianmin
    Zhang, Yibin
    Zheng, Huizhen
    Zhu, Zhenggang
    Wang, Dingming
    Li, Sihai
    Li, Yuhua
    Yang, Liqing
    Zhang, Junnan
    Bai, Yunhua
    Lu, Qiang
    Zhang, Zheng
    Luo, Fengji
    Yu, Chun
    Li, Li
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1338 - 1345
  • [36] EFFECTIVENESS AND TOLERANCE OF PRE- AND POSTEXPOSURE TREATMENT WITH PURIFIED INACTIVATED RABIES VACCINE PREPARED ON VERO CELL-LINE
    KLIETMANN, W
    KLIETMANN, B
    COX, J
    CHARBONNIER, C
    VACCINE, 1988, 6 (01) : 39 - 43
  • [37] Safety and efficacy of purified vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial)
    Jaiiaroensup, W
    Lang, J
    Thipkong, P
    Wimalaratne, O
    Samranwataya, P
    Saikasem, A
    Chareonwai, S
    Yenmuang, W
    Prakongsri, S
    Sitprija, V
    Wilde, H
    VACCINE, 1998, 16 (16) : 1559 - 1562
  • [38] Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd
    Kulkarni, Prasad S.
    Sahai, Ashish
    Gunale, Bhagwat
    Dhere, Rajeev M.
    EXPERT REVIEW OF VACCINES, 2017, 16 (04) : 303 - 311
  • [39] Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults
    Phadke, Varun K.
    Gromer, Daniel J.
    Rebolledo, Paulina A.
    Graciaa, Daniel S.
    Wiley, Zanthia
    Sherman, Amy C.
    Scherer, Erin M.
    Leary, Maranda
    Girmay, Tigisty
    Mccullough, Michele P.
    Min, Ji-Young
    Capone, Stefania
    Sommella, Andrea
    Vitelli, Alessandra
    Retallick, Jamie
    Seetahal, Janine
    Koller, Mark
    Tsong, Rachel
    Neill-Gubitz, Hannah
    Mulligan, Mark J.
    Rouphael, Nadine G.
    VACCINE, 2024, 42 (26)
  • [40] A comparative study on the safety and immunogenecity of purified duck embryo cell vaccine (PDEV, VAXIRAB) with purified chick embryo cell vaccine (PCEC, RABIPUR) and purified vero cell rabies vaccine (PVRV, VERORAB) (vol 28, pg 148, 2010)
    Ashwathnarayana, Doddabele Hanumantaiah
    Madhusudana, Shampur Narayana
    Sampath, Gadey
    Sathpathy, Durga Madhab
    Mankeshwar, Ranjit
    Ravish, Haradana Halli Shankariah
    Ullas, Padinjaremattathil Thankappan
    Behra, Tapas Ranjan
    Sudarshan, Mysore Kalappa
    Gangaboraiah
    Shamanna, Manjula
    VACCINE, 2010, 28 (13) : 2575 - 2575